Mason Street Advisors’s Meridian Bioscience Inc VIVO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q1 | – | Sell |
-16,063
| Closed | -$300K | – | 1377 |
|
|
2020
Q4 | $300K | Sell |
16,063
-18
| -0.1% | -$336 | 0.01% | 1319 |
|
|
2020
Q3 | $273K | Hold |
16,081
| – | – | 0.01% | 1261 |
|
|
2020
Q2 | $375K | Buy |
16,081
+1,194
| +8% | +$17.3K | 0.01% | 1170 |
|
|
2020
Q1 | $125K | Hold |
14,887
| – | – | ﹤0.01% | 1376 |
|
|
2019
Q4 | $145K | Buy |
14,887
+384
| +3% | +$3.6K | ﹤0.01% | 1446 |
|
|
2019
Q3 | $138K | Buy |
14,503
+274
| +2% | +$2.89K | ﹤0.01% | 1430 |
|
|
2019
Q2 | $169K | Buy |
14,229
+583
| +4% | +$7.02K | ﹤0.01% | 1395 |
|
|
2019
Q1 | $240K | Buy |
13,646
+478
| +4% | +$7.95K | ﹤0.01% | 1355 |
|
|
2018
Q4 | $229K | Buy |
13,168
+606
| +5% | +$10.3K | 0.01% | 1277 |
|
|
2018
Q3 | $187K | Buy |
12,562
+334
| +3% | +$5.18K | ﹤0.01% | 1396 |
|
|
2018
Q2 | $194K | Buy |
12,228
+491
| +4% | +$7.32K | ﹤0.01% | 1384 |
|
|
2018
Q1 | $167K | Buy |
11,737
+760
| +7% | +$11.2K | ﹤0.01% | 1386 |
|
|
2017
Q4 | $154K | Buy |
10,977
+288
| +3% | +$4.22K | ﹤0.01% | 1393 |
|
|
2017
Q3 | $153K | Buy |
10,689
+282
| +3% | +$4.03K | ﹤0.01% | 1378 |
|
|
2017
Q2 | $164K | Buy |
10,407
+539
| +5% | +$7.76K | ﹤0.01% | 1346 |
|
|
2017
Q1 | $136K | Buy |
9,868
+667
| +7% | +$9.33K | ﹤0.01% | 1374 |
|
|
2016
Q4 | $163K | Buy |
9,201
+537
| +6% | +$9.43K | ﹤0.01% | 1316 |
|
|
2016
Q3 | $167K | Buy |
8,664
+439
| +5% | +$8.59K | ﹤0.01% | 1266 |
|
|
2016
Q2 | $160K | Buy |
8,225
+750
| +10% | +$14.7K | ﹤0.01% | 1243 |
|
|
2016
Q1 | $154K | Buy |
7,475
+730
| +11% | +$14.4K | ﹤0.01% | 1220 |
|
|
2015
Q4 | $138K | Buy |
6,745
+599
| +10% | +$11.5K | ﹤0.01% | 1229 |
|
|
2015
Q3 | $105K | Buy |
6,146
+384
| +7% | +$7.02K | ﹤0.01% | 1275 |
|
|
2015
Q2 | $107K | Buy |
5,762
+224
| +4% | +$4.15K | ﹤0.01% | 1288 |
|
|
2015
Q1 | $106K | Buy |
5,538
+181
| +3% | +$3.35K | ﹤0.01% | 1280 |
|
|
2014
Q4 | $88K | Buy |
5,357
+170
| +3% | +$2.92K | ﹤0.01% | 1723 |
|
|
2014
Q3 | $92K | Sell |
5,187
-37
| -0.7% | -$727 | ﹤0.01% | 1690 |
|
|
2014
Q2 | $108K | Buy |
5,224
+150
| +3% | +$3.08K | ﹤0.01% | 1652 |
|
|
2014
Q1 | $111K | Sell |
5,074
-1,530
| -23% | -$35.1K | ﹤0.01% | 1616 |
|
|
2013
Q4 | $175K | Buy |
6,604
+502
| +8% | +$12.3K | ﹤0.01% | 1549 |
|
|
2013
Q3 | $144K | Buy |
6,102
+357
| +6% | +$8.34K | ﹤0.01% | 1415 |
|
|
2013
Q2 | $124K | Buy |
+5,745
| New | +$124K | ﹤0.01% | 1359 |
|
Other funds holding VIVO
DM
Mason Street Advisors's VIVO Position: Q1 2021 in Review
Mason Street Advisors sold out of Meridian Bioscience Inc (VIVO) in Q1 2021, closing a stake of 16,063 shares — an estimated $300K sold.
Mason Street Advisors first reported a position in VIVO in Q2 2013 and held it in 31 quarters. The position peaked at $375K in Q2 2020. 215 funds tracked by Wall St. Rank hold VIVO as of Q1 2021.
- Mason Street Advisors reported no remaining Meridian Bioscience Inc position as of Q1 2021 after selling out during the quarter.
- Mason Street Advisors sold 16,063 Meridian Bioscience Inc shares in Q1 2021, an estimated $300K.
- Mason Street Advisors first reported a position in Meridian Bioscience Inc in Q2 2013 and held it in 31 quarters.
- Mason Street Advisors's Meridian Bioscience Inc position peaked at $375K in Q2 2020.
- 215 funds tracked by Wall St. Rank held Meridian Bioscience Inc as of Q1 2021.
Based on Mason Street Advisors's 13F filing for Q1 2021, filed 14 May 2021.